Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IMP9064

Small molecule · Inhibitor of ATR · developed by Impact Therapeutics

Phase 2 Most advanced trial

IBO Developer

1 Registered trials

What is IMP9064?

IMP9064 is an orally bioavailable ATR kinase inhibitor that selectively binds to and inhibits ATR, blocking ATR-mediated signaling and downstream CHK1 phosphorylation. This disrupts DNA damage checkpoint activation and DNA repair, inducing tumor cell apoptosis. It is being studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: ATR, CHK1 (CHEK1) (secondary target)
Mechanism: Inhibitor of ATR
Pathways: DNA damage checkpoint, DNA damage repair, apoptosis
Therapy area: Oncology
Developer: Impact Therapeutics, Inc. (IBO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05269316	Phase 1/2	Solid Tumor	Recruiting	IBO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorSolid Tumor

Other drugs acting on ATR

ATRN-119 Phase 1/2 Ceralasertib Phase 1

More from Impact Therapeutics

IMP4927 Investigational Potrasertib Investigational Senaparib Investigational

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBO page.

Follow IBO, the company behind IMP9064

See IBO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z